Who
Andrew Paul Mazar
Chief Operating Officer
Company insider
Files Form 4 as: Chief Operating Officer, Actuate Therapeutics; Chief Scientific Officer, Monopar Therapeutics.
In numbers
- Trades disclosed
- 29
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 9 Aug 2018
- Last trade
- 1 Apr 2026
- Last filed
- 1 Apr 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Apr 2026filed 1 Apr 2026 | ACTU Actuate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —105,000 at $0.00 | filing |
| 1 Apr 2026filed 1 Apr 2026 | ACTU Actuate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —105,000 at $0.00 | filing |
| 1 Apr 2025filed 2 Apr 2025 | ACTU Actuate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —51,046 at $0.00 | filing |
| 1 Apr 2025filed 2 Apr 2025 | ACTU Actuate Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,346 at $0.00 | filing |
| 31 Mar 2022filed 1 Apr 2022 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,606 at $0.00 | filing |
| 31 Mar 2022filed 1 Apr 2022 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code M | —1,606 | filing |
| 31 Mar 2022filed 1 Apr 2022 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,201471 at $2.55 | filing |
| 2 Feb 2022filed 4 Feb 2022 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —88,874 at $0.00 | filing |
| 2 Feb 2022filed 4 Feb 2022 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —67,251 at $0.00 | filing |
| 1 Jan 2022filed 4 Jan 2022 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,937 at $0.00 | filing |
| 1 Jan 2022filed 4 Jan 2022 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code M | —1,937 | filing |
| 1 Jan 2022filed 4 Jan 2022 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code F | $2,154671 at $3.21 | filing |
| 31 Dec 2021filed 4 Jan 2022 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,606 at $0.00 | filing |
| 31 Dec 2021filed 4 Jan 2022 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code M | —1,606 | filing |
| 31 Dec 2021filed 4 Jan 2022 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code F | $1,785556 at $3.21 | filing |
| 30 Sep 2021filed 1 Oct 2021 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,606 at $0.00 | filing |
| 30 Sep 2021filed 1 Oct 2021 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code M | —1,606 | filing |
| 30 Sep 2021filed 1 Oct 2021 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code F | $2,294471 at $4.87 | filing |
| 30 Jun 2021filed 2 Jul 2021 | MNPR Monopar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,212 at $0.00 | filing |
| 30 Jun 2021filed 2 Jul 2021 | MNPR Monopar TherapeuticsBiotechnology | SEC FORM 4 Code M | —3,212 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.